Dudediligence.

Emergent BioSolutions Inc

EBSNYSE · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$293.8MSep ’24$194.7MDec ’24$222.2MMar ’25$140.9MJun ’25$231.1MSep ’25$148.7MDec ’25$156.1MMar ’26$234.3MJun ’26
Net income, by quarter
$114.8MSep ’24−$31.3MDec ’24$68.0MMar ’25−$12.0MJun ’25$51.2MSep ’25−$54.6MDec ’25$6.8MMar ’26−$180.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$1.77B$1.12B$1.05B$1.04B$742.9M
Gross profit$1.03B$424.4M$343.9M$362.3M$416.7M
Operating income$341.4M−$170.0M−$726.4M−$108.7M$100.1M
Net income$219.5M−$211.6M−$760.5M−$190.6M$52.6M
Operating cash flow$320.2M−$34.1M−$206.3M$58.7M$170.6M
Free cash flow$96.1M−$149.9M−$257.9M$35.8M$156.8M
Cash$576.1M$642.6M$111.7M$99.5M$205.4M
Debt$841.0M$1.41B$860.2M$663.7M$572.1M
Shares outstanding51.3M50.1M52.2M54.3M56.7M